On October 25, 2019, Lepu Biopharma (Beijing) Co., Ltd successfully held the launch ceremony in Pinggu Mafang Industrial Park, for officially put manufacturing plant into use. Shen Jie, deputy secretary of Pinggu District Committee, Wang Tiejiu, director of Management Committee of Mafang Industrial Park and responsible persons of relevant functional departments, Pu Zhongjie, chairman of Lepu Biopharma, Sui Ziye, general manager of Lepu Biopharma, Shen Cong, production director of Lepu Biopharma and other management personnel of the company, Dr. Zhang Faming, chairman of Waterstone, Dr. Fanglei of I-Mab, Dr. Qin Minmin and Dr. Liu Wenchao of Miracogen, Li Haoqiang, general manager of Hangzhou Healsun Biopharma, Gu Xiangyong of Binhui Biotech, Guo Yongqi of Shiyu Capital, Cai Zhiyang of Suzhou Kington Capital ， Yu Zhihua of Lapam Fund and other investors and partners of Lepu Biopharma has attended this event.

 

 

The construction area of Lepu Biopharma(Beijing) manufacturing plant is 12,000 square meters, and one production line of 500 liters and one production line of 2000 liters has been built. Focusing on the cancer immunotherapy business, this manufacturing plant will undertake the critical work of developing and producing innovative cancer treatment products of PD-1, PD-L1 and core combination drugs (oncolytic virus, ADC); meanwhile, it will build an open industrial platform for target discovery, research, development and production of drug and medicine. Through the synergistic effect of the above products and industrial platform, the leap-forward development and sustainable development of Lepu Biopharma can be realized.

 

 

At the launch ceremony, Chairman Pu Zhongjie of Lepu Biopharma said that from the official establishment of Lepu Biopharma in January 2018 to the operation of Beijing Pinggu manufacturing plant in October 2019, we created a new record of "Lepu Speed" again. Based on that, Lepu Biopharma will continue to promote the development of biomedical industry such as cancer immunotherapy, build a whole industrial chain platform for cancer prevention, screening diagnosis, drug therapy, surgical treatment, postoperative rehabilitation and prevention of recurrence, chronic disease management and monitoring that covering the main cancer indications, and thus facilitate the strategic upgrading of the product structure in the pharmaceutical field that is parallel to "take chemical drugs as the basic and new biological new drugs as the development direction". Take "science and technology care for life" as its responsibility, and wholeheartedly protect public health through innovative devices and innovative drugs. 

 

Pu Zhongjie, Chairman of Lepu Biopharma

 

Subsequently, Sui Ziye, General Manager of Lepu Biopharma, Shen Cong, Production Director of Lepu Biopharma, introduced and displayed the manufacturing plant remote imaging. It is also mentioned that the manufacturing plant of Lepu Biopharma (Beijing) has six departments including cell culture department, purification department, preparation department, QA department, QC department and warehouse department, which can complete the whole-process production of upstream cell cultivate, downstream separation and purification, preparation filling, QC product quality monitoring, QA product release and product warehousing. The average age of the employees in this team is 28 years, which is a very young and dynamic team. At present, the manufacturing site has completed the process transfer and clinical sample production, which is expected to meet the requirements for commercial scale production by the end of 2020. 

 

Sui Ziye, General Manager of Lepu Biopharma

 

Shen Cong, Production Director of Lepu Biopharma 

 

Shen Jie, deputy secretary of the Pinggu District Committee, warmly welcomed the settlement of Lepu Biopharma in the industrial park. He pointed out that relying on the advantages of policy resources and location environment, Pinggu Mafang Industrial Park is introducing and fostering a number of high-end medical device enterprises with independent development capacity in accordance with the development principles of "innovation-driven, radiation-guided, regional coordination and green intensification" and turning the industrial park into a medical and health industrial base focusing on medical device production and R & D. As a key project introduced by the industrial park, the manufacturing plant of Lepu Biopharma (Beijing) will certainly become a key and important link in the development of medical and health industry in Mafang Industrial Zone. As an excellent domestic medical enterprise, Lepu Biopharma has made great contributions to public health protection. Pinggu District will provide good services and powerful protection to Lepu Biopharma and is looking forward to work hand in hand with Lepu Biopharma to succeed and to jointly promote the development of China's biomedical industry. 

 

Shen Jie, Deputy Secretary of Pinggu District Committee

 

Next, Zhang Faming, chairman of Waterstone, Co-Scientist of Lepu Biopharma, Dr. Fanglei of I-Mab, and other representatives of Lepu’s suppliers such as ThermoFisher Scientific, Sartorius, GE, and Mettler-Toledo made speeches respectively, indicating that they will work with Lepu Biopharma to create a brilliant future.

 

Dr. Zhang Faming, Chairman of Waterstone 

 

Dr. Lei Fang, I-Mab 

 

Ida Chen, CFO of ThermoFisher Scientific China 

 

Mr. Floris, Sales Director of Sartorius Biotech 

 

Yu Lihua, General Manager of Life Sciences Business Unit of GE Healthcare China

 

Chang Cheng, General Manager of Mettler-Toledo Laboratory

 

Then, Shen Jie, Deputy Secretary of Pinggu District Committee, Pu Zhongjie, Chairman of Lepu Biopharma, Sui Ziye, General Manager of Lepu Biopharma, Shen Cong, Production Director of Lepu Biopharma, Dr. Zhang Faming, Chairman of Waterstone, Dr. Fanglei of I-Mab, Guo Yongqi of Shiyu Capital, Li Haoqiang, General Manager of Hangzhou Healsun Biopharma, and Cai Zhiyang of Suzhou Kington Capital jointly completed a simple and grand launch ceremony, marking the official launch of the manufacturing plant. It is expected that Lepu Biopharma can, like this small tree, take root in the industrial park, and grow into a towering tree, becoming the pillar of China's medical and health industry. After the ceremony, participants visited the plant and workshop. 

 

 

The launch of Lepu Biopharma (Beijing)’s manufacturing plant marks that the Lepu Biooharma Cancer Immunotherapy Industry has stepped into a new stage and will provide new kinetic energy for the company to maintain stable, rapid and sustainable development in the future. Lepu Biopharma Co., Ltd. will take this as an opportunity to continuously improve the layout of biomedical industry such as cancer immunotherapy in accordance with the established objectives, build a whole industrial chain platform covering the main cancer indications, provide patients with whole life cycle medical solutions, and effectively promote the development of cancer immunotherapy in China with the strength of science and technology. 

Lepu Biopharma (Beijing) manufacturing plant